Abstract: A method implemented on an electronic computing device includes displaying a document. An image of a person is received. The image of the person is overlaid onto at least a portion of the image of the document. One or more movements are received from the person. The image of the person is moved to indicate a specific area of the document. The movement of the image of the person to the specific area of the document is based on the one or more movements from the person.

Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.

Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.

Abstract: A seating device can include a seat and a base connected to the seat to support the seat. A tilt mechanism can be connected to at least one of the base and the seat. The tilt mechanism can include at least one of (a) at least one seat connecting member connecting the seat to an upper portion of the base, (b) a plurality of resilient fingers that are attached to the base to engage a floor and flex in response to a user providing a force while sitting or leaning on the seat, and (c) an elastomeric floor engagement member that is attached to the base and has a bottom peripheral portion that contacts a floor and is flexible in response to a user providing the force. In some embodiments, the tilt mechanism may include all of elements (a)-(c).

Abstract: A method includes supplying a conjoined molten glass stream to an overflow distributor. A cross section of the conjoined molten glass stream includes a first cross sectional portion and a second cross sectional portion. The first cross sectional portion includes a first glass composition. The second cross sectional portion includes a second glass composition different than the first glass composition. The first glass composition is flowed over a first transverse segment of a weir of the overflow distributor. The second glass composition is flowed over a second transverse segment of the weir of the overflow distributor.

Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Abstract: A seating device can include a seat and a base connected to the seat to support the seat. A tilt mechanism can be connected to at least one of the base and the seat. The tilt mechanism can include at least one of (a) at least one seat connecting member connecting the seat to an upper portion of the base, (b) a plurality of resilient fingers that are attached to the base to engage a floor and flex in response to a user providing a force while sitting or leaning on the seat, and (c) an elastomeric floor engagement member that is attached to the base and has a bottom peripheral portion that contacts a floor and is flexible in response to a user providing the force. In some embodiments, the tilt mechanism may include all of elements (a)-(c).

Abstract: A lighting system and related methods are disclosed herein. The lighting system may have a mounting fixture and a light fixture. The mounting fixture is configured to engage a mounting surface. The light fixture is configured to engage the mounting fixture and has a driver configured to drive a light source. A first fastener having a movable elongated member is configured to removably couple the light fixture to the mounting fixture in an extended configuration. A second fastener having a quick connect feature is configured to removably couple the light fixture to the mounting fixture in a retracted configuration.

Abstract: The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2, R3, A, W, U and V are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

Abstract: An electrical connection system connecting a flexible conduit to electrical conductors, comprising a conduit portion and a removably attachable base portion. The conduit portion retains an end of the conduit, via a retention mechanism within a first housing at a first end. The conduit portion comprises a first electrical connector housing and electrical terminals within a second end of the first housing. The base portion comprises a base mount and a second housing having a first end pivotably connected to the base mount, the second housing being pivotable at a joint. The base portion may also comprise a second electrical connector housing and electrical terminals within a second end of the second housing for electrical connection to the conduit portion. Mechanical fastening components of the base portion and the conduit portion enable a mechanical connection between the base portion and the conduit portion.

Abstract: In various embodiments, a system for providing an LED illumination source on a surface includes a light module comprising (i) an illumination area for receiving one or more light-emitting diodes (LEDs) and (ii) slip joints at first and second ends of the light module, each slip joint comprising a slip joint slot, and at least one bracket for mounting the light module to the surface, the at least one bracket having (i) a fitting frictionally receivable within one of the slip joint slots and (ii) a mounting region engageable to the surface.

Abstract: The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2, R3, A, W, U and V are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Abstract: A computer implemented method, system, and computer program product include one or more processors providing a framework for building a visual representation of a product concept, the visual representation including one or more of a textual component and a graphical component; one or more processors receiving a designation of an element within at least one of the textual component and the graphical components as a dynamic element; one or more processors associating the dynamic element with a variant list including one or more element variants; one or more processors receiving a selection of a first element variant from the variant list; and one or more processors generating a first instantiation of the visual representation including the first element variant as the dynamic element.

Abstract: A soluble compound for preventing or reducing blood coagulation comprising an antithrombotic agent and a membrane binding element, wherein the antithrombotic agent has a weight of less than about 5,000 daltons. Also disclosed is a soluble compound for preventing or reducing blood coagulation comprising an anticoagulant joined to a membrane binding element via a joining element, wherein the joining element between the anticoagulant and the membrane binding element is less than about 10,000 daltons in weight. These compounds can be used in therapy and, in particular, in preventing or reducing blood coagulation. As a result, a method of treatment is provided comprising administering an effective amount of the compounds to a subject to prevent or reduce blood coagulation as well as a method of perfusing an organ, tissue or cell comprising contacting the compounds with the organ, tissue or cell to prevent or reduce blood coagulation.

Abstract: A framework is provided for building a visual representation of a product concept including a textual component and/or a graphical component. A designation is received of a first element within at least one of the textual component and the graphical components as a dynamic element. The dynamic element is associated with a variant list including one or more element variants. A second element corresponding to the first element is identified. The second element is linked with the first element. A selection of a first element variant from the variant list is received. A first instantiation of the visual representation is generated including the first element variant as the dynamic element and including the first element variant as the second element.

Abstract: Pilots suitable for use in MIMO systems and capable of supporting various functions are described. The various types of pilot include—a beacon pilot, a MIMO pilot, a steered reference or steered pilot, and a carrier pilot. The beacon pilot is transmitted from all transmit antennas and may be used for timing and frequency acquisition. The MIMO pilot is transmitted from all transmit antennas but is covered with different orthogonal codes assigned to the transmit antennas. The MIMO pilot may be used for channel estimation. The steered reference is transmitted on specific eigenmodes of a MIMO channel and is user terminal specific. The steered reference may be used for channel estimation. The carrier pilot may be transmitted on designated subbands/antennas and may be used for phase tracking of a carrier signal. Various pilot transmission schemes may be devised based on different combinations of these various types of pilot.

Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Abstract: A computer implemented method, system, and computer program product include one or more processors providing a framework for building a visual representation of a product concept, the visual representation including one or more of a textual component and a graphical component; one or more processors receiving a designation of an element within at least one of the textual component and the graphical components as a dynamic element; one or more processors associating the dynamic element with a variant list including a plurality of element variants; one or more processors receiving a selection of a subset of the plurality of element variants from the variant list; and one or more processors generating a first instantiation of the visual representation including a combination of the subset of the plurality of element variants as the dynamic element.